AN OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG TERM SAFETY, TOLERABILITY AND EFFICACY OF PF-02545920 IN SUBJECTS WITH HUNTINGTON’S DISEASE WHO PREVIOUSLY COMPLETED STUDY A8241021

Registry ID

EUCTR2014-004900-31

Source registry

EUCTR

Status

Prematurely Ended

Phase

PHASE2

Sponsor

Pfizer Inc, 235 East 42nd Street, New York, NY 10017

Start date

2015-04-21

Completion date

2017-02-06

Last update

2026-08-16

Conditions

• HUNTINGTON'S DISEASE

Summary

- To assess long-term safety and tolerability of 20 mg BID of PF-02545920 in subjects with HD.

Locations

• , , Germany

View on source registry